Ann: Race Board and Management Team Changes, page-144

Well, he got the marching orders I suppose.

A 40% SP reduction from 1.20 to 0.80 was enough for majority shareholders and the board to maybe recognize DCB's corporate persona wasn't going to cut the mustard here.

The comment that the SP decline is because the market doesnt understand the strategy is poor, it is the CEO responsibility that the market interprets the strategy in the best way. The roadshow was a good platform to allow this, but maybe the board doesnt like a CEO that is name dropping BP as being in discussions with them if that happened as people suggested on here.

See how we go from here, but I am not upset over this. I am looking forward to a clinically based CEO.